Margenza (Margetuximab-cmkb) is a HER2/neu receptor antagonist used, in combination with chemotherapy, to treat adult patients with metastatic HER2¬ positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Dosage: The recommended dose of margenza is 15 mg/kg, administered as an intravenous infusion every 3 weeks (21-day cycle) until the disease is progressive or unacceptable toxicity occurs. Administer margenza as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses. On days when both margenza and chemotherapy are to be administered, margenza may be administered immediately after chemotherapy completion.
Side Effects: The most commonly reported margetuximab side effects in combination with chemotherapy include:
- Abdominal pain
- Peripheral neuropathy
- Decreased appetite
- Extremity pain
- Infusion-related reactions
- Palmar-plantar erythrodysesthesia
Warnings and Precautions:
- Patients with margenza dose should contact a health specialist promptly for new onset or worsening shortness of breath, swelling of the ankles/legs, cough, swelling of the face, sudden weight gain, palpitations, dizziness or loss of consciousness.
- Monitor patients for IRRs during margenza uses and as clinically indicated following completion of infusion.
- Conduct cardiac assessment, including history, physical examination, and determination of LVEF through echocardiogram or MUGA scan.
- Verify pregnancy status of respective women of reproductive potential prior to initiation of margetuximab injection.
- Margetuximab can be responsible for causing fetal harm when administered to a pregnant woman.